Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

Wykoff Charles C.; Ou William C.; Khurana Rahul N.; Brown David M.; Clark W. Lloyd; Boyer David S.

首页> 外文期刊>British journal of ophthalmology >Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

【24h】

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

机译：在糖尿病Marumare Marema水肿中可或于急需的AfliBercep：耐力推广研究的2年结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background/aims To evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management.

机译：背景/旨在通过第五年的管理评估个性化2.0mg含有2.0mg含有术治疗糖尿病水肿（DME）的疗效和安全性的疗效和安全性。

著录项

来源
《British journal of ophthalmology》 |2018年第5期|共6页
作者
Wykoff Charles C.; Ou William C.; Khurana Rahul N.; Brown David M.; Clark W. Lloyd; Boyer David S.;
展开▼
作者单位

Retina Consultants Houston Houston TX 77030 USA;

Retina Consultants Houston Houston TX 77030 USA;

Northern Calif Retina Vitreous Associates Mountain View CA USA;

Retina Consultants Houston Houston TX 77030 USA;

Palmetto Retina Ctr W Columbia SC USA;

Retina Vitreous Associates Med Grp Los Angeles CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study [J] . Wykoff Charles C., Ou William C., Khurana Rahul N., British journal of ophthalmology . 2018,第5期

机译：在糖尿病Marumare Marema水肿中可或于急需的AfliBercep：耐力推广研究的2年结果
2. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study REPLY [J] . Wykoff Charles C., Le Ryan T., Khurana Rahul N., American Journal of Ophthalmology: The International Journal of Ophthalmology . 2017,第期

机译：在III阶段Vista DME试验后，可根据需要的AFLiBercept和Marular激光的结果：耐力12个月扩展研究答复
3. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study [J] . Calugaru Dan, Calugaru Mihai American Journal of Ophthalmology: The International Journal of Ophthalmology . 2017,第期

机译：阶段III Vista DME试验后，可根据需要的AfliBercept和Marular激光的结果：耐力12个月扩展研究
4. Morphology of vascular network in eyes with diabetic macular edema varies based on tolerance of aflibercept treatment interval length: preliminary findings [C] . Prateek Prasanna, Justis Ehlers, Nathaniel Braman, Biomedical Applications in Molecular, Structural, and Functional Imaging . 2019

机译：患有糖尿病黄斑水肿的眼睛中血管网络的形态基于AfliBercept治疗间隔长度的耐受性因耐受性而变化：初步调查结果
5. Coping with diabetic peripheral neuropathy: A pilot study examining the impact of coping styles, acceptance, and optimism on the outcome of thermal biofeedback therapy. [D] . Scherdell, Traci. 2010

机译：应对糖尿病周围神经病变：一项初步研究，探讨应对方式，接受度和乐观度对热生物反馈疗法的影响。
6. Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study [O] . Christoph Kern, Johannes Schiefelbein, Dun Jack Fu, 2020

机译：玻璃体腔内注射阿柏西普治疗的糖尿病性黄斑水肿患者两年视力和结构结局–回顾性队列研究
7. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study [O] . Wykoff Charles C., Le Ryan T., Khurana Rahul N., 2017

机译：VISTA DME III期试验后，按需使用阿柏西普和黄斑激光治疗的结果：耐力12个月延长研究

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

摘要

著录项

相似文献

相关主题

期刊订阅